)

Tempest Therapeutics (TPST) investor relations material
Tempest Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Clinical-stage biotech focused on cancer therapies, with amezalpat ready for pivotal Phase 3 in liver cancer and TPST-1495 entering Phase 2 for FAP, both with recent regulatory designations and positive trial data.
Cleared to begin pivotal amezalpat trial for first-line HCC in China, expanding on prior US and EU clearances.
Received orphan drug designations for amezalpat (HCC) and TPST-1495 (FAP) from FDA and EMA.
In April 2025, initiated a strategic review to explore alternatives including mergers, acquisitions, or partnerships, and implemented significant cost reductions including a 21-person workforce reduction.
Key executives transitioned to consulting roles; company retained MTS Health Partners to advise on strategic options.
Financial highlights
Cash and cash equivalents were $14.3 million as of June 30, 2025, down from $30.3 million at December 31, 2024.
Net loss for Q2 2025 was $7.9 million ($2.07/share), a decrease from $9.6 million ($5.52/share) in Q2 2024; net loss for the six months ended June 30, 2025 was $18.7 million ($5.17/share), up from $17.5 million ($10.15/share) year-over-year.
Research and development expenses for Q2 2025 were $3.9 million, down 34% year-over-year; general and administrative expenses increased to $4.1 million, mainly due to one-time separation costs.
Operating cash outflows for the first half of 2025 were $16.5 million, compared to $12.7 million in the prior year period.
Raised $4.1 million in a registered direct offering and $2.8 million via ATM program in H1 2025; repaid $3.5 million to fully satisfy outstanding loan.
Outlook and guidance
Existing cash is expected to fund operations for less than 12 months from the date of the financial statements, raising substantial doubt about going concern.
Advancement of amezalpat into Phase 3 and TPST-1495 into Phase 2 is contingent on securing additional resources or a strategic transaction.
Actively pursuing strategic alternatives to advance clinical programs and maximize stockholder value.
Ongoing strategic review may result in mergers, acquisitions, partnerships, or other transactions; no timetable set for completion.
Next Tempest Therapeutics earnings date

Next Tempest Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage